carfilzomib / Generic mfg.  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

9 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
carfilzomib / Generic mfg.
NCT00999414: UARK 2009-32 Compassionate Use Study of Carfilzomib

No Longer Available
N/A
US
Carfilzomib
University of Arkansas, Onyx Therapeutics, Inc.
Multiple Myeloma
04/15
04/15
NCT01410500: Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease

Approved for marketing
N/A
NA
Carfilzomib, Kyprolis®
Amgen, Multiple Myeloma Research Foundation
Multiple Myeloma
 
 
PROTECT, NCT02178579: Prospective Observation of Cardiac Safety With Proteasome Inhibition

Completed
N/A
95
US
Vanderbilt University Medical Center, Takeda
Heart Failure, Multiple Myeloma
07/19
07/19
NCT03091127: Real-world Use of Carfilzomib Among Multiple Myeloma Patients in Europe

Completed
N/A
705
Europe, RoW
Amgen
Multiple Myeloma
03/20
03/20
NCT03724097: Identification of Molecular Biomarkers for Cancer Target Therapy Efficacy

Active, not recruiting
N/A
200
US, RoW
RNA sequencing, RNA-seq, Transcriptome analysis, target drug with the score above 0,1, target drug with the score equal or below 0,1, non-target drug, palliative care
OmicsWay Corp., Oncobox Ltd, Vitamed LLC, N.N. Blokhin National Medical Research Center of Oncology, Kaluga Regional Clinical Oncology Center, Multidisciplinary medical holding SM-Clinic, Oncological Clinical Dispensary No. 1 of the Moscow City Health Department
Cancer
04/21
11/22
NCT04004338: Carfilzomib in Combination for the Treatment of RR MM

Unknown status
N/A
300
RoW
Kyprolis
Black Sea Hematology Association, Amgen
Multiple Myeloma, Relapse Multiple Myeloma, Refractory Multiple Myeloma
04/21
04/21
NCT03763370: Expanded Access Request Program for Belantamab Mafodotin (GSK2857916) in Multiple Myeloma

Available
N/A
NA
Belantamab mafodotin (GSK2857916) anti-BCMA-immunoconjugate
GlaxoSmithKline
Multiple Myeloma
 
 
CARO, NCT02970747: Non-interventional Study of Kyprolis® in Combination With Revlimid® and Dexamethasone or Dexamethasone Alone or in Combination With Darzalex® and Dexamethasone in Multiple Myeloma Patients

Active, not recruiting
N/A
359
Europe
Carfilzomib, Kyprolis®
iOMEDICO AG, Amgen
Multiple Myeloma in Relapse
06/25
06/25
IONA-MM, NCT04458831: A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)

Recruiting
N/A
1200
Europe, Japan, US, RoW
isatuximab SAR650984, Sarclisa, Pomalidomide, Pomalyst, Dexamethasone, Carfilzomib
Sanofi
Plasma Cell Myeloma
02/26
02/26

Download Options